Icon
+91 94997 68112
Login Register

Pedmark - (12.5 g/100 mL; Solution, Intravenous)

Sodium Thiosulfate Fennec Pharms
12.5 g/100 mL; Solution, Intravenous
Less Than $1000 mn
Less Than 5
Less Than 5
None None
None None
PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors
Yes
** *** **, **** **** ******* *********** ***** * ********* *** *** ** ******* '*** *** '*** **** *** ****, *** ******** ** ***** ** ***** *******. ** *********** ******* ** *** **, ****. ** ** ******** *** ****** ****** ****.
Pedmark Patent 1 Patent 2 Patent 3 Patent 4
***** ********* ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** / ********* *** **, **** ******* **** *** ****** *** **, **** (** ***********)
  1. *** *, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** *, **** : ***** ******** ****** ** ***** **** ** ******.
  3. *** **, **** : ****** ****** **** ***** **** ************ ** ******* ’***, ’***, *** ’*** ('*** *** ****** ***** ).
  4. *** **, **** : ****** ****** ***** ** ******* ********* ******* *****, ***** **** **** **** ******* '*** *** '***. *** '*** ****** ** **** ** ****** ********.
  5. *** **, **** : ****** ****** ***** * ****** ******* ********* ******* *****, ***** **** **** ******* '***, '*** *** ***** ****** ****** '***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.